Download our whitepaper,

"Understanding Glaucoma: Epidemiology, Clinical Implications & Strategies for Clinical Trial Success"

iNGENu_Glaucoma_Clinical_Trials_CRO

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for Glaucoma Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for Glaucoma.
  • Comprehensive Analysis of FDA-Approved Glaucoma Drugs.
  • How Diagnostic Criteria for Glaucoma Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in Glaucoma Clinical Trials.
  • And additional insights to drive your trial's success.

Access your complimentary whitepaper today:

Glaucoma Clinical Trials

Glaucoma is a complex eye condition characterized by the damage to the optic nerve, often associated with elevated intraocular pressure, leading to progressive, irreversible vision loss.

Glaucoma is recognized as the leading cause of blindness for individuals over the age of 60. However, blindness from glaucoma can often be prevented with early diagnosis and treatment.

The evolving understanding of glaucoma has significantly influenced clinical practice and research endeavors. Clinicians now embrace a comprehensive approach in diagnosing and managing glaucoma, taking into account patient-specific factors, coexisting conditions, and variations in disease manifestation.

In research, there is a growing emphasis on identifying glaucoma subtypes, investigating non-pharmacological interventions, and elucidating the long-term prognosis for individuals affected by glaucoma.


Glaucoma affects around

3%

of the population aged 40-80 globally

 



Glaucoma is the

2nd

leading cause of blindness worldwide

 

 


By 2030, an estimated

112m

people will have glaucoma


Our clinical team has over

120

years of combined clinical trial experience